# A Study to Evaluate the Pharmacokinetics and Safety of YHD1119 in Subjects With Renal Impairment and Healthy Subjects

> **NCT05012436** · PHASE1 · COMPLETED · sponsor: **Yuhan Corporation** · enrollment: 16 (actual)

## Conditions studied

- Healthy Volunteer
- Renal Impairments

## Interventions

- **DRUG:** YHD1119 75mg

## Key facts

- **NCT ID:** NCT05012436
- **Lead sponsor:** Yuhan Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-24
- **Primary completion:** 2022-05-10
- **Final completion:** 2022-05-10
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05012436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05012436, "A Study to Evaluate the Pharmacokinetics and Safety of YHD1119 in Subjects With Renal Impairment and Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05012436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*